

Arndt Vogel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7449223/publications.pdf>

Version: 2024-02-01

286
papers

20,636
citations

22548

61
h-index

14779

131
g-index

327
all docs

327
docs citations

327
times ranked

19701
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	6.1	19
2	Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2137-2144.	1.2	1
3	Medical therapy of HCC. <i>Journal of Hepatology</i> , 2022, 76, 208-210.	1.8	11
4	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
5	State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. <i>Liver International</i> , 2022, 42, 288-298.	1.9	5
6	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
7	Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. <i>Trends in Cancer</i> , 2022, 8, 83-86.	3.8	6
8	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial). <i>Journal of Clinical Oncology</i> , 2022, 40, 303-303.	0.8	1
9	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 378-378.	0.8	146
10	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs). <i>Journal of Clinical Oncology</i> , 2022, 40, 399-399.	0.8	1
11	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS494-TPS494.	0.8	2
12	ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS498-TPS498.	0.8	7
13	mRNA therapeutics for liver diseases: HNF4A mRNA delivery via lipid nanoparticles attenuates liver fibrosis in preclinical models. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
14	Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
15	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	1.8	119
16	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	0.9	35
17	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210802.	1.4	43
18	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114

#	ARTICLE	IF	CITATIONS
19	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	1.3	43
20	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
21	Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. <i>Cancers</i> , 2022, 14, 118.	1.7	12
22	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1213-1226.	2.0	9
23	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	3.2	32
24	Performance evaluation of the Elecsys <sc>PIVKA-II</sc> and Elecsys AFP assays for hepatocellular carcinoma diagnosis. <i>JGH Open</i> , 2022, 6, 292-300.	0.7	10
25	Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, 1, .		267
26	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	17
27	Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15584-e15584.	0.8	0
28	Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4078-4078.	0.8	0
29	Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4075-4075.	0.8	7
30	Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4074-4074.	0.8	2
31	IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)â€”Updated efficacy results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4116-4116.	0.8	7
32	Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4070-4070.	0.8	9
33	Quality of life and outcome of patients with metastatic pancreatic cancer receiving firstâ€”line chemotherapy with nabâ€”paclitaxel and gemcitabine: Realâ€”life results from the prospective <sc>QOLIXANE</sc> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. <i>International Journal of Cancer</i> , 2021, 148, 1478-1488.	2.3	13
34	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1237-1251.	1.1	31
35	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
36	Evaluation of a Motion Correction Algorithm for C-Arm Computed Tomography Acquired During Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 610-618.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110311.	1.4	19
38	Targeted therapies in cholangiocarcinoma: Assessment of US oncologist practice patterns.. <i>Journal of Clinical Oncology</i> , 2021, 39, 347-347.	0.8	1
39	ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110399.	1.4	7
40	p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1387-1404.	2.3	3
41	The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 1-8.	0.8	9
42	Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 928-936.	0.7	11
43	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	2.9	39
44	Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 257-261.	1.7	6
45	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
46	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 240-248.	4.2	39
47	Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4029-4029.	0.8	2
48	The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4159-TPS4159.	0.8	1
49	The PLATON pilot-study "Platform for analyzing targetable tumor mutations" A PLATON network study.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6598-TPS6598.	0.8	0
50	Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4100-4100.	0.8	17
51	Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4086-4086.	0.8	18
52	Advances in systemic therapy for the first-line treatment of unresectable HCC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 621-628.	1.1	11
53	IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4073.	0.8	52
54	Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3222.	1.7	20

#	ARTICLE	IF	CITATIONS
55	High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy. <i>World Journal of Gastroenterology</i> , 2021, 27, 3630-3642.	1.4	6
56	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. <i>Clinical Cancer Research</i> , 2021, 27, 4848-4858.	3.2	39
57	Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2803.	1.0	14
58	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021, 32, 801-805.	0.6	235
59	The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 705485.	2.2	19
60	BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. <i>Der Pathologe</i> , 2021, 42, 98-109.	0.7	5
61	Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. <i>Journal of Hepatology</i> , 2021, 75, 1420-1433.	1.8	70
62	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	3.7	58
63	The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1357-1370.	3.6	13
64	Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3837.	1.0	1
65	P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. , 2021, , .		1
66	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1132-1143.	0.8	2
67	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1468-1482.	5.1	30
68	Current and Future Systemic Therapies in Biliary Tract Cancer. <i>Visceral Medicine</i> , 2021, 37, 32-38.	0.5	5
69	Perioperative chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone in gallbladder carcinoma or in front of radical resection in BTC: The phase III GAIN trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS353-TPS353.	0.8	0
70	Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).. <i>Journal of Clinical Oncology</i> , 2021, 39, 298-298.	0.8	10
71	Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 510-521.	4.2	23
72	Immunotherapies in clinical development for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 351-363.	1.9	28

#	ARTICLE	IF	CITATIONS
73	Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells. <i>Frontiers in Immunology</i> , 2021, 12, 790775.	2.2	0
74	Generation of focal mutations and large genomic deletions in the pancreas using inducible <i>in vivo</i> genome editing. <i>Carcinogenesis</i> , 2020, 41, 334-344.	1.3	7
75	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020, 72, 88-102.	3.6	76
76	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	3.6	92
77	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 728-735.e4.	2.4	167
78	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
79	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 93-104.	4.2	60
80	Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells. <i>Gut</i> , 2020, 69, 1104-1115.	6.1	37
81	Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101946.	3.4	104
82	Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. <i>Abdominal Radiology</i> , 2020, 45, 3326-3336.	1.0	4
83	FGFR inhibitors in cholangiocarcinoma: what's now and what's next?. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095329.	1.4	33
84	Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 683-692.	1.7	10
85	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	2.9	37
86	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
87	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. <i>Liver Cancer</i> , 2020, 9, 440-454.	4.2	10
88	Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 917-918.	1.9	0
89	Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study. <i>Cancers</i> , 2020, 12, 3149.	1.7	2
90	Adjuvant 131I-metuximab in hepatocellular carcinoma: a new option for an old drug?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 517-519.	3.7	5

#	ARTICLE	IF	CITATIONS
91	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	1.9	17
92	Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3003-3012.	1.2	18
93	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	5.1	923
94	Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. <i>Liver International</i> , 2020, 40, 1225-1238.	1.9	16
95	Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR) – the AIO/ CALGPI/ ACCO- GAIN-trial –. <i>BMC Cancer</i> , 2020, 20, 122.	1.1	45
96	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS – ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <i>Annals of Oncology</i> , 2020, 31, 334-351.	0.6	138
97	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). <i>Annals of Oncology</i> , 2020, 31, 228-235.	0.6	60
98	Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <i>International Journal of Cancer</i> , 2020, 147, 2493-2502.	2.3	22
99	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. <i>Cell Death and Disease</i> , 2020, 11, 212.	2.7	90
100	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	1.9	26
101	The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1160-1168.	1.9	17
102	Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. <i>Annals of Oncology</i> , 2020, 31, 789-797.	0.6	62
103	Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 4585-4585.	0.8	8
104	Real-life results from the prospective QoliXane trial of the platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry. <i>Journal of Clinical Oncology</i> , 2020, 38, 4625-4625.	0.8	1
105	Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2020, 38, e16601-e16601.	0.8	4
106	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. <i>Journal of Clinical Oncology</i> , 2020, 38, 477-477.	0.8	26
107	Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2020, 38, 518-518.	0.8	15
108	Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). <i>Journal of Clinical Oncology</i> , 2020, 38, 524-524.	0.8	12

#	ARTICLE	IF	CITATIONS
109	FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with <i>FGFR2</i> fusions or rearrangements.. Journal of Clinical Oncology, 2020, 38, TPS592-TPS592.	0.8	14
110	Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC): A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR)â€”The AIO/CALGP/ACO-GAIN-Trial.. Journal of Clinical Oncology, 2020, 38, TPS4653-TPS4653.	0.8	0
111	Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2020, 38, 520-520.	0.8	2
112	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	6.1	100
113	Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter. CardioVascular and Interventional Radiology, 2019, 42, 1441-1448.	0.9	9
114	Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice. Nutrients, 2019, 11, 2486.	1.7	6
115	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver International, 2019, 39, 714-726.	1.9	49
116	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open, 2019, 4, e000491.	2.0	140
117	Endoscopic biliary drainage in patients with cholangiocarcinoma â€” self-expanding metal versus polyethylene stents. Scandinavian Journal of Gastroenterology, 2019, 54, 640-645.	0.6	3
118	LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype. PLoS ONE, 2019, 14, e0216374.	1.1	12
119	RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncology, 2019, 15, 1811-1822.	1.1	99
120	Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. Scientific Reports, 2019, 9, 4338.	1.6	10
121	Programmed cell death proteinâ€”1 (PDâ€”1)â€”targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre realâ€”world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	1.9	106
122	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Targeted Oncology, 2019, 14, 115-123.	1.7	19
123	Secondâ€”line chemotherapy in biliary tract cancer: Outcome and prognostic factors. Liver International, 2019, 39, 914-923.	1.9	25
124	Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro. Hepatology Communications, 2019, 3, 423-436.	2.0	25
125	Immunotherapy: New Options in Gastrointestinal Cancers?. Visceral Medicine, 2019, 35, 47-51.	0.5	1
126	Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. Cancers, 2019, 11, 1868.	1.7	5

#	ARTICLE	IF	CITATIONS
127	Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. <i>Cancers</i> , 2019, 11, 1904.	1.7	11
128	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 203-217.	4.2	48
129	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019, 8, 41-65.	4.2	38
130	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 387-402.	4.2	18
131	Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2019, 44, 1554-1561.	1.0	21
132	Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. <i>International Journal of Cancer</i> , 2019, 144, 2782-2794.	2.3	19
133	Percutaneous hepatic perfusion (chemosaturtion) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. <i>European Radiology</i> , 2019, 29, 1882-1892.	2.3	31
134	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 186-186.	0.8	35
135	Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 371-371.	0.8	10
136	Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS462-TPS462.	0.8	5
137	Anti-angiogenics in Hepatocellular Cancer Therapy. , 2019, , 435-446.		0
138	Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 264-264.	0.8	0
139	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 238-246.	1.6	17
140	Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE. <i>Abdominal Radiology</i> , 2018, 43, 3288-3300.	1.0	3
141	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study. <i>European Journal of Cancer</i> , 2018, 92, 11-19.	1.3	55
142	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. <i>Oncology Research and Treatment</i> , 2018, 41, 298-304.	0.8	8
143	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 1163-1173.	6.3	3,542
144	Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1475-1483.	0.2	82

#	ARTICLE	IF	CITATIONS
145	Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads. <i>Abdominal Radiology</i> , 2018, 43, 1245-1253.	1.0	12
146	OWE-016â€¦Genetic variants in PNPLA3 and TM6SF2 predispose to hepatocellular carcinoma in patients with alcohol-related cirrhosis. , 2018, , .		4
147	Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. <i>Scientific Reports</i> , 2018, 8, 17452.	1.6	22
148	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv238-iv255.	0.6	663
149	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816
150	Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1991-1999.	1.2	13
151	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 13-26.	2.0	34
152	First-line molecular therapies in the treatment of metastatic colorectal cancer â€“ a literature-based review of phases II and III trials. <i>Innovative Surgical Sciences</i> , 2018, 3, 85-86.	0.4	6
153	Interferonâ€free therapy of chronic hepatitis C with directâ€acting antivirals does not change the shortâ€term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 516-525.	1.9	65
154	Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice. <i>Oncogenesis</i> , 2017, 6, e294-e294.	2.1	17
155	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	2.9	66
156	Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 864-872.	0.9	37
157	Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1730-1738.	1.4	17
158	Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1559-1566.	0.9	24
159	Treatment decisions in metastatic colorectal cancer â€“ Beyond first and second line combination therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 54-60.	3.4	99
160	Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2113-2121.	1.2	26
161	Anti-angiogenics in Hepatocellular Cancer Therapy. , 2017, , 1-12.		0
162	Cholangiocellular Carcinoma. <i>Digestion</i> , 2017, 95, 181-185.	1.2	17

#	ARTICLE	IF	CITATIONS
163	The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1347-1355.	1.2	28
164	Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma â€” a caseâ€”control study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1398-1406.	0.6	1
165	Risk estimation for biliary tract cancer: Development and validation of a prognostic score. <i>Liver International</i> , 2017, 37, 1852-1860.	1.9	21
166	Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1. <i>Advances in Experimental Medicine and Biology</i> , 2017, 959, 49-64.	0.8	13
167	Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 116-124.	0.6	13
168	FOLFOX/Bevacizumab +/â” Irinotecan in advanced colorectal cancer (AIO) â€œCHARTAâ€” Final results and multivariate prognostic factor analysis. <i>Annals of Oncology</i> , 2017, 28, iii152.	0.6	0
169	Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. <i>Diagnostic and Interventional Radiology</i> , 2017, 23, 217-222.	0.7	15
170	Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. <i>Deutsches A&#x0308;rzteblatt International</i> , 2017, 114, 597-602.	0.6	9
171	The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction â€” a phase III trial of the German AIO/CAO-V/CAOGI. <i>BMC Cancer</i> , 2017, 17, 893.	1.1	128
172	Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1647-1656.	0.8	18
173	â€œCHARTAâ€” FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancerâ€”Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3533-3533.	0.8	14
174	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4001-4001.	0.8	65
175	A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4027-4027.	0.8	10
176	ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4142-TPS4142.	0.8	17
177	A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4-4.	0.8	16
178	CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)â€”Final results of the randomized phase II trial of the AIO (KRK 0209).. <i>Journal of Clinical Oncology</i> , 2017, 35, 658-658.	0.8	5
179	Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS509-TPS509.	0.8	5
180	<i>hsa-mir-183</i> is frequently methylated and related to poor survival in human hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 1568.	1.4	17

#	ARTICLE	IF	CITATIONS
181	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4870-4879.	3.2	26
182	Future Therapy of Cholangiocarcinoma. <i>Visceral Medicine</i> , 2016, 32, 431-433.	0.5	0
183	Surveillance in cholangiocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 987-999.	1.0	25
184	Epidemiology and Risk Factors of Cholangiocarcinoma. <i>Visceral Medicine</i> , 2016, 32, 395-400.	0.5	124
185	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	2.9	150
186	Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC. <i>Biological Chemistry</i> , 2016, 397, 1147-1162.	1.2	3
187	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	2.4	217
188	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 296-304.	1.8	26
189	Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. <i>Annals of Oncology</i> , 2016, 27, 1273-1279.	0.6	65
190	Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. <i>Cancer Treatment Reviews</i> , 2016, 50, 142-147.	3.4	19
191	Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. <i>Cancer Cell</i> , 2016, 30, 308-323.	7.7	68
192	Transarterial Chemoembolization versus Resection in Patients with Large, Solitary Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1773-1774.	0.2	1
193	Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). <i>BMC Cancer</i> , 2016, 16, 817.	1.1	28
194	Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. <i>Advances in Therapy</i> , 2016, 33, 2122-2138.	1.3	21
195	Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. <i>European Radiology</i> , 2016, 26, 3447-3455.	2.3	14
196	Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9067-9067.	0.8	41
197	Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 441-441.	0.8	0
198	Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15602-e15602.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Treatment strategies in patients with hepatocellular carcinoma in a real-life cohort.. Journal of Clinical Oncology, 2016, 34, e15630-e15630.	0.8	0
200	Treatment of Non-Colorectal Liver Metastases. Visceral Medicine, 2015, 31, 441-443.	0.5	0
201	Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncology Research and Treatment, 2015, 38, 596-603.	0.8	20
202	The BH3-only protein BID impairs the p38-mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice. Hepatology, 2015, 62, 816-828.	3.6	9
203	Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology, 2015, 62, 1524-1535.	3.6	115
204	Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival. Clinical Epigenetics, 2015, 7, 110.	1.8	14
205	Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experience. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 131-137.	1.4	46
206	Cholangiocarcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 219.	1.0	0
207	Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events. Oncology Research and Treatment, 2015, 38, 300-308.	0.8	14
208	Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. Clinical Science, 2015, 128, 761-774.	1.8	23
209	Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 345-353.	1.0	26
210	Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterology, 2015, 15, 60.	0.8	42
211	A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Letters, 2015, 369, 396-404.	3.2	29
212	MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. Journal of Hepatology, 2015, 62, 101-110.	1.8	35
213	Chronic liver inflammation and hepatocellular carcinogenesis are independent of $S100A8/A9$. International Journal of Cancer, 2015, 136, 2458-2463.	2.3	9
214	Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).. Journal of Clinical Oncology, 2015, 33, 4033-4033.	0.8	13
215	Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced KRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. Journal of Clinical Oncology, 2015, 33, 4082-4082.	0.8	8
216	In Reply. Deutsches Ärztblatt International, 2015, 112, 373.	0.6	0

#	ARTICLE	IF	CITATIONS
217	The Diagnosis and Treatment of Cholangiocarcinoma. <i>Deutsches Arzteblatt International</i> , 2014, 111, 748-54.	0.6	35
218	p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury. <i>Gut</i> , 2014, 63, 1501-1512.	6.1	45
219	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 57.	3.8	515
220	The Pathogenesis of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 545-553.	0.8	45
221	Preferences of colorectal cancer patients for treatment and decision-making: a systematic literature review. <i>European Journal of Cancer Care</i> , 2014, 23, 762-772.	0.7	24
222	Human and Mouse <i>VEGFA</i> -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. <i>Cancer Discovery</i> , 2014, 4, 730-743.	7.7	165
223	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. <i>Oncologist</i> , 2014, 19, 1156-1168.	1.9	90
224	Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 107.	1.2	110
225	Deregulation of <i>RB1</i> expression by loss of imprinting in human hepatocellular carcinoma. <i>Journal of Pathology</i> , 2014, 233, 392-401.	2.1	38
226	Is There Any Evidence for a Role of Local Treatment in Cholangiocarcinoma?. <i>Viszeralmedizin</i> , 2014, 30, 6-6.	0.0	3
227	Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4028-4028.	0.8	0
228	First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. <i>In Vivo</i> , 2014, 28, 1135-40.	0.6	6
229	The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice. <i>Hepatology</i> , 2013, 58, 1143-1152.	3.6	74
230	MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. <i>Hepatology</i> , 2013, 57, 299-310.	3.6	132
231	Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. <i>Hepatology</i> , 2013, 58, 363-373.	3.6	83
232	A Direct <i>In Vivo</i> RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration. <i>Cell</i> , 2013, 153, 389-401.	13.5	127
233	Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker. <i>International Journal of Cancer</i> , 2013, 133, 660-670.	2.3	68
234	Activity of the <i>mTOR</i> inhibitor RAD001, the dual <i>mTOR</i> and <i>PI3K</i> inhibitor BEZ235 and the <i>PI3K</i> inhibitor BKM120 in hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 780-793.	1.9	38

#	ARTICLE	IF	CITATIONS
235	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. <i>Annals of Oncology</i> , 2013, 24, 2342-2349.	0.6	89
236	Nrf2 Activates Augmenter of Liver Regeneration (ALR) via Antioxidant Response Element and Links Oxidative Stress to Liver Regeneration. <i>Molecular Medicine</i> , 2013, 19, 237-244.	1.9	78
237	Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. <i>Liver Transplantation</i> , 2013, 19, 1252-1261.	1.3	88
238	Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients. <i>PLoS ONE</i> , 2013, 8, e80454.	1.1	24
239	Hepatocyte-specific S100a8 and S100a9 transgene expression in mice causes Cxcl1 induction and systemic neutrophil enrichment. <i>Cell Communication and Signaling</i> , 2012, 10, 40.	2.7	17
240	Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. <i>Cell Death and Disease</i> , 2012, 3, e295-e295.	2.7	54
241	Hyperkeratoses as paraneoplastic syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 593-595.	0.4	0
242	Hyperkeratosen als paraneoplastisches Syndrom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 593-595.	0.4	0
243	Mimics of Autoimmune Hepatitis: Drug Induced and Immune Mediated Liver Disease. , 2012, , 93-113.		1
244	Loss of Imprinting and Allelic Switching at the DLK1-MEG3 Locus in Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e49462.	1.1	119
245	mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma. <i>Current Cancer Drug Targets</i> , 2012, 12, 1045-1061.	0.8	10
246	Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography – A prospective study. <i>Digestive and Liver Disease</i> , 2011, 43, 484-490.	0.4	68
247	Genotyping of the UDP-Glucuronosyltransferase (UGT) 1A7 Gene Revisited. <i>Gastroenterology</i> , 2011, 140, 1692-1693.	0.6	10
248	Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. <i>Hepatology</i> , 2009, 50, 500-509.	3.6	39
249	Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. <i>Hepatology</i> , 2009, 50, 1130-1139.	3.6	92
250	The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers. <i>Hepatology</i> , 2009, 50, 1558-1566.	3.6	37
251	Akt and 14-3-3 Control a PACS-2 Homeostatic Switch that Integrates Membrane Traffic with TRAIL-Induced Apoptosis. <i>Molecular Cell</i> , 2009, 34, 497-509.	4.5	61
252	The BH3-Only Protein Bid Does Not Mediate Death-Receptor-Induced Liver Injury in Obstructive Cholestasis. <i>American Journal of Pathology</i> , 2009, 175, 1077-1085.	1.9	23

#	ARTICLE	IF	CITATIONS
253	Searching high and low: Cancer stem cells in the eye. <i>Hepatology</i> , 2008, 47, 2136-2137.	3.6	1
254	Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. <i>Hepatology</i> , 2008, 48, 487-496.	3.6	36
255	Loss of p21 Permits Carcinogenesis from Chronically Damaged Liver and Kidney Epithelial Cells despite Unchecked Apoptosis. <i>Cancer Cell</i> , 2008, 14, 59-67.	7.7	60
256	Nuclear Factor-Eythroid 2â€“Related Factor 2 Prevents Alcohol-Induced Fulminant Liver Injury. <i>Gastroenterology</i> , 2008, 134, 1159-1168.e2.	0.6	173
257	Murine Embryonic Stem Cell-Derived Hepatic Progenitor Cells Engraft in Recipient Livers with Limited Capacity of Liver Tissue Formation. <i>Cell Transplantation</i> , 2008, 17, 313-323.	1.2	53
258	Immunopathogenesis of Extrahepatic Manifestations in HAV, HBV, and HCV Infections. , 2007, , 209-217.		1
259	Äkute und chronische nichtvirale Hepatitiden: Autoimmunerkrankungen, Medikamente und Toxine. , 2007, , 910-915.		0
260	Sustained Phosphorylation of Bid Is a Marker for Resistance to Fas-Induced Apoptosis During Chronic Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 104-119.	0.6	31
261	Autoimmune hepatitis, from mechanisms to therapy. <i>Hepatology</i> , 2006, 43, S132-S144.	3.6	159
262	Identification and Characterization of a Functional TATA Box Polymorphism of the UDP Glucuronosyltransferase 1A7 Gene. <i>Molecular Pharmacology</i> , 2005, 67, 1732-1739.	1.0	72
263	Long-term outcome of liver transplantation for autoimmune hepatitis. <i>Clinical Transplantation</i> , 2004, 18, 62-69.	0.8	140
264	UGT1A7 polymorphisms, polycyclic aromatic hydrocarbons and the development of hepatocellular cancer. <i>Hepatology</i> , 2004, 40, 1021-1021.	3.6	2
265	Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. <i>Hepatology</i> , 2004, 39, 433-443.	3.6	61
266	Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. <i>Hepatology</i> , 2004, 39, 970-977.	3.6	146
267	77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. <i>Genes and Immunity</i> , 2003, 4, 79-81.	2.2	74
268	UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. <i>Gastroenterology</i> , 2003, 124, 1802-1808.	0.6	135
269	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	1.8	401
270	Autoimmunity and hepatitis C. <i>Autoimmunity Reviews</i> , 2003, 2, 322-331.	2.5	60

#	ARTICLE	IF	CITATIONS
271	A Novel AIRE Mutation in an APECED Patient with Candidiasis, Adrenal Failure, Hepatitis, Diabetes Mellitus and Osteosclerosis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 174-176.	0.6	5
272	Lupus-like Panniculitis in a Patient with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 288-293.	0.6	12
273	Polymorphisms of the Carcinogen Detoxifying UDP-Glucuronosyltransferase UGT1A7 in Proximal Digestive Tract Cancer. <i>Zeitschrift Fur Gastroenterologie</i> , 2002, 40, 497-502.	0.2	41
274	Autoimmunity and viruses. <i>Clinics in Liver Disease</i> , 2002, 6, 739-753.	1.0	23
275	The genetic background of autoimmune polyendocrinopathyâ€œcandidiasisâ€œectodermal dystrophy and its autoimmune disease components. <i>Journal of Molecular Medicine</i> , 2002, 80, 201-211.	1.7	98
276	Autoimmune hepatitis and overlap syndromes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S389-S398.	1.4	15
277	Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. <i>Gut</i> , 2002, 50, 851-856.	6.1	116
278	Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. <i>Hepatology</i> , 2002, 35, 126-131.	3.6	231
279	Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. <i>Gastroenterology</i> , 2001, 121, 1136-1144.	0.6	125
280	Autoimmune regulator AIRE: Evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. <i>Hepatology</i> , 2001, 33, 1047-1052.	3.6	58
281	Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy. <i>Zeitschrift Fur Gastroenterologie</i> , 2001, 39, 837-840.	0.2	6
282	Presentation, Management and Outcome of Cholangiocarcinoma in Europe: Results From Real-World Patient Registry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
283	Pemigatinib for Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
284	Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
285	The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
286	Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0